Work

Biomimetic Nanoparticle Delivering Colchicine to Target Endothelial Inflammation for Atherosclerosis Treatment

Year: 2026

Type: article

Abstract: Dysfunctional endothelium with chronic inflammation represents an early stage in the development of atherosclerotic plaques. Nanomedicines capable of targeting activated endothelium and resolving inflammation have great potential for atherosclerosis treatment. In this work, we developed biomimetic platelet membrane‐coated layered double hydroxide nanoparticles (PM‐LDH) for the targeted delivery of anti‐inflammatory drug colchicine to the inflamed endothelial cells and showed improved therapeutic effects by using the colchicine‐loaded PM‐LDH. Inspired by the natural interactions between platelets and activated endothelium, platelet membrane‐coated nanoparticles exhibited markedly high affinity for inflamed endothelial cells while reducing immune clearance by macrophages. The enhanced anti‐inflammatory efficacy was demonstrated by reduced monocyte recruitment and attenuated reactive oxygen species production in inflamed endothelial cells. Overall, through the platelet membrane–endothelium interaction, the biomimetic colchicine‐loaded nanoparticles show strong potential as a targeted therapeutic strategy for atherosclerosis.

Source: Advanced NanoBiomed Research

DOI: 10.1002/anbr.202600004

Authors: Xiuwen Zhang, Lingqing Zong, Ashish Misra, Sanjay Patel, Zi Gu

Institutions: UNSW Sydney, The Heart Research Institute, Royal Prince Alfred Hospital

Language: English

Topic: Nanoparticle-Based Drug Delivery

Subfield: Biomaterials

Field: Materials Science

Domain: Physical Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,940